NO3049208T3 - - Google Patents

Info

Publication number
NO3049208T3
NO3049208T3 NO14741534A NO14741534A NO3049208T3 NO 3049208 T3 NO3049208 T3 NO 3049208T3 NO 14741534 A NO14741534 A NO 14741534A NO 14741534 A NO14741534 A NO 14741534A NO 3049208 T3 NO3049208 T3 NO 3049208T3
Authority
NO
Norway
Application number
NO14741534A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934967&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO3049208(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO3049208T3 publication Critical patent/NO3049208T3/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/10—Protein-tyrosine kinases (2.7.10)
    • C12Y207/10001—Receptor protein-tyrosine kinase (2.7.10.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO14741534A 2012-12-14 2014-06-30 NO3049208T3 (cg-RX-API-DMAC10.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261737276P 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
NO3049208T3 true NO3049208T3 (cg-RX-API-DMAC10.html) 2018-04-14

Family

ID=50934967

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14741534A NO3049208T3 (cg-RX-API-DMAC10.html) 2012-12-14 2014-06-30

Country Status (11)

Country Link
US (3) US9822347B2 (cg-RX-API-DMAC10.html)
EP (2) EP3326622B1 (cg-RX-API-DMAC10.html)
JP (2) JP6345690B2 (cg-RX-API-DMAC10.html)
AU (3) AU2013359179B2 (cg-RX-API-DMAC10.html)
CA (1) CA2894539C (cg-RX-API-DMAC10.html)
DK (2) DK3326622T3 (cg-RX-API-DMAC10.html)
ES (2) ES2862335T3 (cg-RX-API-DMAC10.html)
FI (1) FI2931265T6 (cg-RX-API-DMAC10.html)
NO (1) NO3049208T3 (cg-RX-API-DMAC10.html)
PT (2) PT3326622T (cg-RX-API-DMAC10.html)
WO (1) WO2014093690A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056999A1 (en) * 2010-01-22 2011-07-28 Amato J. Giaccia Inhibition of axl signaling in anti-metastatic therapy
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
US9822347B2 (en) 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
CA2909669C (en) 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
EP3233902B1 (en) * 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor
EP3703731A4 (en) * 2017-11-04 2021-07-21 Aravive Biologics, Inc. METHOD OF TREATMENT OF METASTATIC CANCER USING AXL DECOY RECEPTORS
WO2023039254A1 (en) * 2021-09-11 2023-03-16 Aravive Inc Methods of treating locally advanced or metastatic pancreatic adenocarcinoma using axl decoy receptors as first-line therapy

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4458066A (en) 1980-02-29 1984-07-03 University Patents, Inc. Process for preparing polynucleotides
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
US5538861A (en) 1994-07-29 1996-07-23 Amgen Inc. DNA encoding a stimulating factor for the axl receptor
US20030082767A1 (en) 1997-09-18 2003-05-01 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP1382969A1 (en) 2002-07-17 2004-01-21 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Diagnosis and prevention of cancer cell invasion
AU2003304180A1 (en) 2002-09-24 2005-01-04 Dow, Kenneth, Centocor, Inc. Growth arrest specific gene 6 peptides, antibodies, compositions, methods and uses
US20070142273A1 (en) 2003-04-18 2007-06-21 Sherif Daouti Methods and compositions targeting tyrosine kinases for the diagnosis and treatment of osteoarthritis
JP2005278631A (ja) 2004-03-04 2005-10-13 National Institute Of Advanced Industrial & Technology Ａｘｌリガンド結合領域蛋白質、その製造方法及びそれを用いたスクリーニング方法
WO2006058202A2 (en) 2004-11-24 2006-06-01 The Regents Of The University Of Colorado Mer diagnostic and therapeutic agents
US7932032B2 (en) 2005-05-02 2011-04-26 Toray Industries, Inc. Method for diagnosing esophageal cancer
EP2114983B8 (en) * 2007-02-07 2015-02-18 The Regents of the University of Colorado, A Body Corporate Axl tyrosine kinase inhibitors and methods of making and using the same
AU2008240188A1 (en) 2007-04-13 2008-10-23 Supergen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
EP2170395A1 (en) 2007-07-02 2010-04-07 Wyeth LLC Modulators of axl for use in treating bone disorders
WO2010014755A1 (en) 2008-07-29 2010-02-04 The Regents Of The University Of Colorado Methods and compounds for enhancing anti-cancer therapy
BRPI0923442A2 (pt) * 2008-12-19 2016-01-12 Novartis Ag polipeptídeos solúveis para uso em tratamento de distúrbio autoimunes e inflamatórios.
AR076564A1 (es) 2009-05-11 2011-06-22 U3 Pharma Gmbh Anticuerpos humanizados de axl(receptor de tirosina quinasa)
US9074192B2 (en) * 2010-01-22 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL signaling in anti-metastatic therapy
CA3056999A1 (en) 2010-01-22 2011-07-28 Amato J. Giaccia Inhibition of axl signaling in anti-metastatic therapy
CA2817197C (en) 2010-11-08 2020-08-04 The Board Of Trustees Of The Leland Stanford Junior University Fusion proteins comprising an engineered knottin peptide and uses thereof
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
WO2014093707A1 (en) 2012-12-14 2014-06-19 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of axl signaling in primary tumor therapy
US9822347B2 (en) * 2012-12-14 2017-11-21 The Board Of Trustees Of The Leland Stanford Junior University Modified AXL peptides and their use in inhibition of AXL signaling in anti-metastatic therapy
WO2015030849A1 (en) * 2013-08-30 2015-03-05 The Board Of Trustees Of The Leland Stanford Junior University High-affinity binding to gas6
CA2909669C (en) * 2014-10-20 2023-12-12 Ruga Corporation Antiviral activity of gas6 inhibitor
EP3233902B1 (en) * 2014-12-18 2020-09-09 Aravive Biologics, Inc. Antifibrotic activity of gas6 inhibitor

Also Published As

Publication number Publication date
US9822347B2 (en) 2017-11-21
US20150315553A1 (en) 2015-11-05
CA2894539A1 (en) 2014-06-19
CA2894539C (en) 2021-09-28
EP3326622B1 (en) 2021-01-20
PT2931265T (pt) 2018-04-16
US20220220458A1 (en) 2022-07-14
WO2014093690A1 (en) 2014-06-19
JP6832887B2 (ja) 2021-02-24
DK2931265T3 (en) 2018-04-16
EP2931265B3 (en) 2023-04-05
EP2931265B1 (en) 2018-01-31
AU2017272193A1 (en) 2017-12-21
AU2019210662A1 (en) 2019-08-22
HK1256071A1 (en) 2019-09-13
PT3326622T (pt) 2021-04-07
AU2013359179A1 (en) 2015-07-02
FI2931265T6 (fi) 2023-05-23
EP3326622A1 (en) 2018-05-30
JP6345690B2 (ja) 2018-06-20
ES2862335T3 (es) 2021-10-07
ES2665323T7 (es) 2023-06-15
AU2013359179B2 (en) 2017-10-05
US11136563B2 (en) 2021-10-05
ES2665323T3 (es) 2018-04-25
JP2018154641A (ja) 2018-10-04
AU2019210662B2 (en) 2021-07-01
US20180030422A1 (en) 2018-02-01
EP2931265A4 (en) 2016-08-31
JP2016510309A (ja) 2016-04-07
DK3326622T3 (da) 2021-04-06
EP2931265A1 (en) 2015-10-21
DK2931265T6 (da) 2023-05-01

Similar Documents

Publication Publication Date Title
BR112014017635A2 (cg-RX-API-DMAC10.html)
BR112014017614A2 (cg-RX-API-DMAC10.html)
BR112014017625A2 (cg-RX-API-DMAC10.html)
BR112014017659A2 (cg-RX-API-DMAC10.html)
BR112014017607A2 (cg-RX-API-DMAC10.html)
BR112014017592A2 (cg-RX-API-DMAC10.html)
BR112014017646A2 (cg-RX-API-DMAC10.html)
BR112014018648A2 (cg-RX-API-DMAC10.html)
BR112014017638A2 (cg-RX-API-DMAC10.html)
AR092201A1 (cg-RX-API-DMAC10.html)
BR112013027865A2 (cg-RX-API-DMAC10.html)
BR112014017609A2 (cg-RX-API-DMAC10.html)
BR112014017644A2 (cg-RX-API-DMAC10.html)
BR112014017634A2 (cg-RX-API-DMAC10.html)
BR112014017647A2 (cg-RX-API-DMAC10.html)
BR112014013184A8 (cg-RX-API-DMAC10.html)
BR112014017618A2 (cg-RX-API-DMAC10.html)
BR112014017627A2 (cg-RX-API-DMAC10.html)
BR112014017623A2 (cg-RX-API-DMAC10.html)
BR112014017652A2 (cg-RX-API-DMAC10.html)
BR112014017630A2 (cg-RX-API-DMAC10.html)
BR112014017641A2 (cg-RX-API-DMAC10.html)
BR112014017631A2 (cg-RX-API-DMAC10.html)
BR112014017622A2 (cg-RX-API-DMAC10.html)
BR112014017589A2 (cg-RX-API-DMAC10.html)